Peripheral endocannabinoid system-mediated actions of rimonabant on growth hormone secretion are ghrelin-dependent

Journal of Neuroendocrinology

Volumn 22, Issue 11, 2010, Pages 1127-1136

  Al Massadi, O ^a,b   Gabellieri, E ^c   Trujillo, M L ^d   Senaris R ^d   Pagotto, U ^e   Pasquali, R ^e   Casanueva, F F ^a,b,d   Seoane, L M ^a,b  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^d UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^e UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Cannabinoids; Ghrelin; Growth hormone (GH)

Indexed keywords

CANNABINOID 1 RECEPTOR; ENDOCANNABINOID; GHRELIN; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; MESSENGER RNA; RIMONABANT; SOMATOSTATIN;

ANIMAL EXPERIMENT; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; GROWTH HORMONE RELEASE; HYPOTHALAMUS; IN SITU HYBRIDIZATION; MALE; METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULSATILE HORMONE RELEASE; RAT; VAGOTOMY; VAGUS NERVE;

EID: 77958567243     PISSN: 09538194     EISSN: 13652826     Source Type: Journal    
DOI: 10.1111/j.1365-2826.2010.02065.x     Document Type: Article

References (39)

1. Hollister LE. Health aspects of cannabis. Pharmacol Rev 1986; 38: 1-20.
2. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006; 27: 73-100.
3. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006; 58: 389-462.
4. Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 2008; 7: 438-455.
5. Kovacs M, Kineman RD, Schally AV, Zarandi M, Groot K, Frohman LA. Effects of antagonists of growth hormone-releasing hormone (GHRH) on GH and insulin-like growth factor I levels in transgenic mice overexpressing the human GHRH gene, an animal model of acromegaly. Endocrinology 1997; 138: 4536-4542.
6. Dalterio SL, Michael SD, Macmillan BT, Bartke A. Differential effects of cannabinoid exposure and stress on plasma prolactin, growth hormone and corticosterone levels in male mice. Life Sci 1981; 28: 761-766.
7. Kokka N, Garcia JF. Effects of delta 9-THC on growth hormone and ACTH secretion in rats. Life Sci 1974; 15: 329-338.
8. Martin-Calderon JL, Munoz RM, Villanua MA, Del Arco I, Moreno JL, De Fonseca FR, Navarro M. Characterization of the acute endocrine actions of (-)-11-hydroxy-delta8-tetrahydrocannabinol-dimethylheptyl (HU-210), a potent synthetic cannabinoid in rats. Eur J Pharmacol 1998; 344: 77-86.
9. Rettori V, Wenger T, Snyder G, Dalterio S, McCann SM. Hypothalamic action of delta-9-tetrahydrocannabinol to inhibit the release of prolactin and growth hormone in the rat. Neuroendocrinology 1988; 47: 498-503.
10. Rettori V, Aguila MC, Gimeno MF, Franchi AM, McCann SM. In vitro effect of delta 9-tetrahydrocannabinol to stimulate somatostatin release and block that of luteinizing hormone-releasing hormone by suppression of the release of prostaglandin E2. Proc Natl Acad Sci USA 1990; 87: 10063-10066.
11. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Neliat G, Caput D. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994; 350: 240-244.
12. Pagotto U, Pasquali R. Pharmacological therapy for visceral obesity at the gates of dawn: the cannabinoid receptor type 1 antagonist. Obes Metab 2006; 2: 1-5.
13. Rodriguez de Fonseca F. Should we ever treat obesity? The case of Rimonabant. Obes Metab 2008; 4: 190-192.
14. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007; 370: 1706-1713.
15. Mallo F, Lamas JA, Casanueva FF, Dieguez C. Effect of retinoic acid deficiency on in vivo and in vitro GH responses to GHRH in male rats. Neuroendocrinology 1992; 55: 642-647.
16. Seoane LM, Lopez M, Tovar S, Casanueva FF, Senaris R, Dieguez C. Agouti-related peptide, neuropeptide Y, and somatostatin-producing neurons are targets for ghrelin actions in the rat hypothalamus. Endocrinology 2003; 144: 544-551.
17. Veldhuis JD, Johnson ML. Cluster analysis: a simple, versatile, and robust algorithm for endocrine pulse detection. Am J Physiol 1986; 250: E486-E493.
18. Seoane LM, Al-Massadi O, Caminos JE, Tovar SA, Dieguez C, Casanueva FF. Sensory stimuli directly acting at the central nervous system regulate gastric ghrelin secretion. an ex vivo organ culture study. Endocrinology 2007; 148: 3998-4006.
19. Carro E, Senaris RM, Seoane LM, Frohman LA, Arimura A, Casanueva FF, Dieguez C. Role of growth hormone (GH)-releasing hormone and somatostatin on leptin-induced GH secretion. Neuroendocrinology 1999; 69: 3-10.
20. Seoane LM, Tovar S, Baldelli R, Arvat E, Ghigo E, Casanueva FF, Dieguez C. Ghrelin elicits a marked stimulatory effect on GH secretion in freely-moving rats. Eur J Endocrinol 2000; 143: R7-R9.
21. Maghnie M, Pennati MC, Civardi E, Di IN, Aimaretti G, Foschini ML, Corneli G, Tinelli C, Ghigo E, Lorini R, Loche S. GH response to ghrelin in subjects with congenital GH deficiency: evidence that ghrelin action requires hypothalamic-pituitary connections. Eur J Endocrinol 2007; 156: 449-454.
22. Herling AW, Kilp S, Elvert R, Haschke G, Kramer W. Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed wistar rats. Endocrinology 2008; 149: 2557-2566.
23. Popovic V, Miljic D, Micic D, Damjanovic S, Arvat E, Ghigo E, Dieguez C, Casanueva FF. Ghrelin main action on the regulation of growth hormone release is exerted at hypothalamic level. J Clin Endocrinol Metab 2003; 88: 3450-3453.
24. Jbilo O, Ravinet-Trillou C, Arnone M, Buisson I, Bribes E, Peleraux A, Penarier G, Soubrie P, Le FG, Galiegue S, Casellas P. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 2005; 19: 1567-1569.
25. Date Y, Murakami N, Toshinai K, Matsukura S, Niijima A, Matsuo H, Kangawa K, Nakazato M. The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology 2002; 123: 1120-1128.
26. Storr MA, Sharkey KA. The endocannabinoid system and gut-brain signalling. Curr Opin Pharmacol 2007; 7: 575-582.
27. Bouaboula M, Perrachon S, Milligan L, Canat X, Rinaldi-Carmona M, Portier M, Barth F, Calandra B, Pecceu F, Lupker J, Maffrand JP, Le FG, Casellas P. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J Biol Chem 1997; 272: 22330-22339.
28. Hillard CJ, Muthian S, Kearn CS. Effects of CB(1) cannabinoid receptor activation on cerebellar granule cell nitric oxide synthase activity. FEBS Lett 1999; 459: 277-281.
29. Burdyga G, Lal S, Varro A, Dimaline R, Thompson DG, Dockray GJ. Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin. J Neurosci 2004; 24: 2708-2715.
30. Gomez R, Navarro M, Ferrer B, Trigo JM, Bilbao A, Del Arco I, Cippitelli A, Nava F, Piomelli D, Rodriguez de FF. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 2002; 22: 9612-9617.
31. Rubino T, Realini N, Castiglioni C, Guidali C, Vigano D, Marras E, Petrosino S, Perletti G, Maccarrone M, Di Marzo V, Parolaro D. Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex. Cereb Cortex 2008; 18: 1292-1301.
32. Verty AN, McFarlane JR, McGregor IS, Mallet PE. Evidence for an interaction between CB1 cannabinoid and melanocortin MCR-4 receptors in regulating food intake. Endocrinology 2004; 145: 3224-3231.
33. Verty AN, McFarlane JR, McGregor IS, Mallet PE. Evidence for an interaction between CB1 cannabinoid and oxytocin receptors in food and water intake. Neuropharmacology 2004; 47: 593-603.
34. Hill MN, Froese LM, Morrish AC, Sun JC, Floresco SB. Alterations in behavioral flexibility by cannabinoid CB1 receptor agonists and antagonists. Psychopharmacology (Berl) 2006; 187: 245-259.
35. Rodriguez de FF, Wenger T, Navarro M, Murphy LL. Effects of delta9-THC on VIP-induced prolactin secretion in anterior pituitary cultures: evidence for the presence of functional cannabinoid CB1 receptors in pituitary cells. Brain Res 1999; 841: 114-122.
36. Dalterio S, Bartke A, Mayfield D. Delta9-tetrahydrocannabinol increase plasma testosterone concentrations in mice. Science 1981; 213: 581-583.
37. Brown AJ. Novel cannabinoid receptors. Br J Pharmacol 2007; 152: 567-575.
38. Begg M, Pacher P, Batkai S, Osei-Hyiaman D, Offertaler L, Mo FM, Liu J, Kunos G. Evidence for novel cannabinoid receptors. Pharmacol Ther 2005; 106: 133-145.
39. Schneider HJ, Pagotto U, Stalla GK. Central effects of the somatotropic system. Eur J Endocrinol 2003; 149: 377-392.